Global Health COVID-19 Standard Indicators

Proposed Collection Instrument
Guidance
ADS 201 states that activities must have an approved Activity Monitoring, Evaluation, and
Learning Plan (AMELP) and directs an OU’s Program Office, Activity Planners, and
COR/AOR/GATR to work with COs/AOs to ensure that the AMELP is a requirement in an
award or agreement. AMELPs are intended to be updated periodically to reflect changes in
activity design, implementation, context, or data needs.
The COVID-19 pandemic necessitated significant changes to existing activities and the
designation of new performance indicators to account for these changes. The USAID COVID-19
Technical Working Group, working with the Interagency COVID MEL TWG and USAID
implementing partners, developed the Global Health COVID-19 Indicators Package (May 2022)
(henceforth referred to as the “Package”). The Package contains a set of harmonized indicators
(Appendix 1) for monitoring and results reporting for global health COVID-19 programming, in
line with the U.S. Global Response and Recovery Framework (GRRF), the USAID COVID-19
Implementation Plan for the GRRF, the Agency Learning Agenda, and the Agency COVID-19
Monitoring, Evaluation and Learning Plan. These indicators were further adapted after the
December, 2021 announcement of the Initiative for Global Vaccine Access (Global VAX).
To streamline and centralize reporting on COVID-19 Global Health standard indicators, USAID
developed a COVID-19 Global Health module in the Development Information Solution (DIS)
web-based reporting system.
AOs and COs should work with OUs to ensure that applicable indicators from the Package are
incorporated, as relevant, into the AMELPs of all applicable agreements and awards. AMELP
revisions should specify that data must be submitted through the DIS at the frequency specified
in their awards; either quarterly or semi-annually. Where these updates imply additional costs for
IPs, agreements or awards, AOs and COs must work with AORs/CORs and activity managers
and the USAID COVID-19 Response Team to ensure sufficient funds are made available–in new
obligations or through CLIN realignments–to cover the costs.
Given the changing nature of the pandemic and evolving shape of the U.S. Government
response, the Global Health COVID-19 Indicators Package may be updated to capture changing
activity design. Any changes to the COVID-19 Global Health standard indicators below will be
made by the Global Health COVID-19 Technical Working Group. AOs and COs must ensure
that all AMELPs are updated with any changes to the standard indicators.
Applicability
This guidance applies to new and existing agreements and awards with NGOs and contractors in
Global VAX surge and “significant investment” countries (those receiving at least $4.275 million
in COVID-19 Global VAX programming from CN239 and CN240): Angola, Côte d’Ivoire,
Eswatini, Ghana, Lesotho, Nigeria, Senegal, South Africa, Tanzania, Uganda, and Zambia
(Global VAX surge countries); Mozambique, Madagascar, Malawi, Liberia, and Ethiopia
(CN240), and Haiti and the Philippines (CN239).

Appendix
Indicator

Indicator Type

Data Source

Reporting
Responsibility

Frequency

Disaggregation

Objective 1: Accelerate widespread and equitable access to and delivery of safe and effective COVID-19 vaccinations
Number of people
reached through
USG-supported mass
media and social media
with COVID-19
vaccine-related
messaging

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Mass Media Type

Number of vaccine doses
delivered to designated
in-country destinations
with USG support

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Vaccine Brand

Number of staff and
volunteers trained on
COVID-19
vaccine-related topics
with USG support

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Sex
Topic Area

Number of health
workers who are
remunerated by USG to
support workload
required for COVID-19
vaccine delivery in the
reporting period

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Cadre

Number of vaccination
sites supported by USG
during the reporting

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Types

period
Number of people who
received a first dose of an
approved COVID-19
vaccine (COV-1) with
USG direct support

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Sex
Vaccine Brand

Number of people who
received a last
recommended dose of
primary series of an
approved COVID-19
vaccine (COV-c) with
USG direct support

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Sex
Vaccine Brand

Number of people who
received a booster dose
of an approved
COVID-19 vaccine
(COV-2,3,4) with USG
direct support

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Sex
Vaccine Brand

Number of adverse event
following immunization
(AEFI) reports reviewed
by the appropriate
responsible bodies with
USG support among
those submitted to
country monitoring
systems

Adaptive
Management
(Output)

Partner reports

Implementing Partners

Quarterly

Type of USG Support
Severity of event